Verrica Pharmaceuticals Inc (VRCA) 2025 Conference May 07, 2025 03:00 PM ET Speaker0 Go ahead. Go ahead and get started here. So thank you everybody for joining us, this afternoon at the Citizens Life Science Conference. Excited to be joined next by Verica Pharmaceuticals. Verica is a company focused on, dermatology medicines, has an approved product for Molluscum. I've joined here this afternoon by Jason Reger, the CEO. So Jason, appreciate you being here and look forward to running through the story. Spea ...

Company Overview - Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing medications for skin diseases that require medical interventions [3] - The company's product YCANTH (VP-102) is the first and only FDA-approved treatment for molluscum contagiosum, a viral skin infection affecting approximately 6 million people in the U.S., primarily children [3] - YCANTH (VP-102) is also being developed to address common warts, which represent a significant unmet need in medical dermatology [3] - Verrica has entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma [3] Upcoming Events - The company will host a conference call and live webcast on May 13, 2025, at 4:30 p.m. ET to discuss its financial results for Q1 2025 and provide a corporate update [1] - Participants can join the call via telephone or through a live audio webcast available on the company's investor relations website [2]

Company Overview - Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing medications for skin diseases that require medical interventions [3] - The company's product YCANTH (VP-102) is the first and only FDA-approved treatment for molluscum contagiosum, a viral skin infection affecting approximately 6 million people in the U.S., primarily children [3] - YCANTH (VP-102) is also being developed to address common warts, which represent a significant unmet need in medical dermatology [3] - Verrica has entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma [3] Upcoming Event - Jayson Rieger, PhD, MBA, President and CEO of Verrica, will present at the Citizens Life Sciences Conference in New York City on May 7, 2025, at 3:00 pm ET [1][2] - Participants can access a live webcast of the event through a link provided, with a replay available for 90 days post-event [2]

– Company generated quarterly sequential growth with Q1 YCANTH® dispensed applicator units rising above 10,000 for the first time in a quarter – – As YCANTH distributor inventory levels have normalized, Company expects that dispensed applicator units will now more closely track demand and gross revenue – WEST CHESTER, Pa., April 07, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases req ...

WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Gavin Corcoran, M.D. to its Board of Directors. “We are pleased to welcome Dr. Gavin Corcoran to our Board of Directors,” said Jayson Rieger, Ph.D., MBA, President and Chief Executive Officer of Verrica Pharmaceuticals. “Gavin is a highly a ...

Shares of Verrica Pharmaceuticals Inc. (VRCA) have been struggling lately and have lost 15.3% over the past week. However, a hammer chart pattern was formed in its last trading session, which could mean that the stock found support with bulls being able to counteract the bears. So, it could witness a trend reversal down the road. Hammer candles can occur on any timeframe -- such as one-minute, daily, weekly -- and are utilized by both short-term as well as long-term investors. Like every technical indicator ...

Company Overview - Verrica Pharmaceuticals Inc. is a dermatology therapeutics company focused on developing medications for skin diseases that require medical interventions [3] - The company's product YCANTH (VP-102) is the first and only FDA-approved treatment for molluscum contagiosum, a viral skin infection affecting approximately 6 million people in the U.S., primarily children [3] - YCANTH (VP-102) is also being developed to address common warts, which represent a significant unmet need in medical dermatology [3] - Verrica has entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for non-melanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma [3] Event Participation - Jayson Rieger, PhD, MBA, President and CEO of Verrica, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference [1] - The conference will take place from April 7-10, 2025, with Verrica's session scheduled for April 8, 2025, at 1:30 pm ET [2] - Participants can access a live webcast of the event through Verrica's website, with a replay available for 90 days post-event [2]

Core Viewpoint - Verrica Pharmaceuticals has appointed Dr. Noah L. Rosenberg as Chief Medical Officer, aiming to enhance its clinical programs and establish YCANTH as the standard treatment for molluscum contagiosum [1][2]. Company Overview - Verrica Pharmaceuticals is focused on developing medications for skin diseases requiring medical interventions, with its flagship product YCANTH being the first FDA-approved treatment for molluscum contagiosum [8]. - YCANTH is a drug-device combination product that effectively treats a highly contagious skin disease affecting approximately 6 million people in the U.S., primarily children [7][8]. Appointment of Chief Medical Officer - Dr. Noah L. Rosenberg brings over 30 years of experience in clinical and therapeutic development, having held senior positions in various biotechnology companies [2]. - His previous roles include Chief Medical Officer at Travere Therapeutics and Medimetriks Pharmaceuticals, where he led the development and approval of significant dermatological products [2]. Financial Incentives - As part of his appointment, Dr. Rosenberg was granted a stock option award to purchase 325,000 shares of Verrica's common stock at an exercise price of $0.5221 per share [3][5]. - The stock option will vest over time, with specific conditions tied to Dr. Rosenberg's continued service with the company [6]. Product Development and Market Potential - YCANTH has shown positive results in clinical trials, demonstrating safety and efficacy for treating molluscum contagiosum, with approximately 225 million lives eligible for insurance coverage [7]. - The company is also developing treatments for common warts and has a licensing agreement with Lytix Biopharma to develop VP-315 for non-melanoma skin cancers [8].

Core Viewpoint - Verrica Pharmaceuticals has appointed Dr. Noah L. Rosenberg as Chief Medical Officer to enhance its drug development efforts, particularly for YCANTH® and other clinical-stage programs [2][8]. Company Overview - Verrica Pharmaceuticals is focused on developing medications for skin diseases requiring medical interventions, with its flagship product YCANTH® being the first FDA-approved treatment for molluscum contagiosum [8]. - The company is also working on treatments for common warts and has a licensing agreement with Lytix Biopharma AS for developing VP-315 for non-melanoma skin cancers [8]. Appointment of Chief Medical Officer - Dr. Noah L. Rosenberg brings over 30 years of experience in clinical and therapeutic development, having held senior positions in various biotechnology companies [2][8]. - His previous roles include Chief Medical Officer at Travere Therapeutics and Medimetriks Pharmaceuticals, where he led the development of significant products [2][8]. - The appointment is seen as a strategic move to advance Verrica's clinical programs and establish YCANTH® as a standard treatment for molluscum contagiosum [2][8]. Stock Option Grant - In connection with Dr. Rosenberg's appointment, he was granted a stock option award to purchase 325,000 shares of Verrica's common stock at an exercise price of $0.5221 per share [3][5]. - The stock option will vest over time, contingent on his continuous service with the company [5][6]. Product Information - YCANTH® is a proprietary drug-device combination product that effectively treats molluscum contagiosum, impacting approximately six million people in the U.S., primarily children [7][8]. - The product is available for $25 per treatment, with financial assistance options for patients in need [7].

Financial Data and Key Metrics Changes - In Q4 2024, total revenues were $0.3 million, primarily from YCANTH revenue, with full-year revenues of $7.6 million compared to $5.1 million in the previous year [27][28] - Gross profit margins for the full year 2024 were reported at 72% [30] - GAAP net loss for Q4 2024 was $16.2 million or $0.24 per share, compared to a loss of $24.6 million or $0.53 per share in Q4 2023 [33] - For the full year 2024, GAAP net loss was $76.8 million or $1.48 per share, compared to a loss of $67 million or $1.48 per share in the prior year [33] Business Line Data and Key Metrics Changes - YCANTH dispense applicator units increased to 8,654 in Q4 2024 from 7,706 in Q3 2024, representing a sequential growth of 12.3% and a 44.8% increase compared to Q2 2024 [15][28] - Research and development expenses decreased to $1.2 million in Q4 2024 from $4.2 million in Q4 2023, primarily due to reduced clinical trial costs [31] - Selling, general, and administrative expenses decreased to $10 million in Q4 2024 from $16.8 million in Q4 2023, reflecting cost-saving measures [32] Market Data and Key Metrics Changes - The company is focusing on territories with high prevalence of molluscum contagiosum to drive demand for YCANTH [13] - The collaboration revenue for the full year 2024 was $1 million, up from $0.5 million in 2023, related to supplies and development activities with Torri [30] Company Strategy and Development Direction - The company is executing a turnaround plan with a focused commercialization strategy for YCANTH while reducing costs [7][8] - There is a strong emphasis on advancing late-stage pipeline programs, including YCANTH for common warts and VP-315 for basal cell carcinoma [11][12] - The company aims to achieve cash-positive monthly operating results by the end of 2025 [48] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the adoption of YCANTH and the overall growth trajectory, noting early positive momentum in 2025 [52][53] - The company is cautiously optimistic about achieving growth in the business and is focused on building long-term relationships with healthcare providers [40][41] Other Important Information - The company raised approximately $42 million in an equity follow-on offering in November 2024 [12][26] - As of December 31, 2024, the company had cash and cash equivalents of $46.3 million, which may not be sufficient to fund operations for the next year without additional milestone payments or warrant exercises [34] Q&A Session Summary Question: What is the patient demand for YCANTH and feedback from clinicians? - Management reported good adoption and interest in YCANTH across both pediatricians and dermatologists, with continued use of the product [49][50] Question: What are the expectations for sales in 2025? - Management indicated that they would leave guidance where analysts have set it for now, remaining cautiously optimistic about growth [53][54] Question: What are the seasonal impacts on demand? - Management noted that warmer weather could support growth, and they are preparing for potential seasonal changes [61][62] Question: What are the barriers to generic entry for YCANTH? - The company has a robust IP portfolio and is addressing challenges from compounders, with good adoption of the product [65][66] Question: What is the impact of expanding usage into the pediatric setting? - Management noted growth in the pediatric market, with a mix of dermatologists and pediatricians treating patients with YCANTH [72][73] Question: What are the plans for moving VP-315 into Phase 3 trials? - Management indicated that the majority of expenses for the VP-315 program were incurred previously, and they will evaluate the program once they have the necessary data [75][76] Question: What is needed to achieve significant demand growth? - Management emphasized the importance of acquiring new customers and increasing utilization among existing customers, along with expanding into larger markets [81][82]